index - Epidemiology in dermatology and evaluation of therapeutics Accéder directement au contenu

DOCUMENTS

79

 

NOTICES

153

 

 

MOTS CLES

Alitretinoin Biologic therapy Treatment Antibiotic misuse Ankylosing Acute Myeloid Leukaemia AML Biosimilar Pharmaceuticals Anticancer drugs Angiotensin receptor blockers Biological therapy Angiotensin-converting enzyme inhibitors Prostate cancer Access to care Apremilast Cancer Primary adrenal insufficiency Antibiotics Immune-related adverse events Infliximab Burden Vigibase® Amyloidosis Epidemiology Adalimumab Antimicrobials Calcium channel blockers Atrial fibrillation Biologic Psoriasis Cardiotoxicity Drug survival Placebo Endocrine toxicity ArtThese Alcohol Auto-Diagnostic Albinism Anxiété Adverse side effects Ankylosing spondylitis Spondyloarthritis Apre-milast Adolescent Ethics Cardiovascular therapy Atopic dermatitis Biomarkers ASDAS Aging Cardio-oncology Abus d'antibiotiques Graft-versus-host disease Cardiomyopathy BTK protein Auto-immune hepatitis Cardiovascular risk Drug reaction Pharmacovigilance Sipuleucel-T Sacroiliitis Biologic drug CTLA-4 Ustekinumab Cattle Antimicrobial resistance Biomédicaments Bacterial rhinosinusitis Psoriatic arthritis Quality of life Antimicrobiens Azathioprine Addiction Méta-Analyse Case-Control Studies COVID-19 Stability Care pathway CSK tyrosine-protein kinase Intensive care Accelerometer Arrhythmia Autoimmune diseases Immune checkpoint inhibitors Anti-TNF Immunotherapy Pharmacoepidemiology Glucocorticoids Biologics Meta-Analysis Dermatology Beta-lactam antibiotics Arthritis Antibiotic resistance Axial spondyloarthritis Biological Therapy Etanercept Anti-HCV Direct Acting Antivirals DAA Anxiety Management Autoimmunity

 

 

 

Epidemiology in Dermatology and Evaluation of therapeutics , EA 7379

Adresse

Université Paris-Est Créteil Val de Marne (UPEC)

Campus Centre de Créteil
61 Avenue du Général de Gaulle
94010 Créteil Cedex

Courriel

emilie.sbidian@aphp.fr

Site Internet

 

Rattachement(s)

UFR de Santé

Direction

Émilie SBIDIAN

 

Axe(s) de recherche

 


[legende-image]65[/legende-image] Axe 1 : Comment mieux gérer les patients ayant développé des réactins graves aux médicaments, notamment en leur indiquant comment utiliser correctement les agents


[legende-image]65[/legende-image] Axe 2 : Rechercher les facteurs associés aux effets indesirables et à l'efficacité du médicament

 
 

COLLABORATIONS